沙利鲁单抗联合甲氨蝶呤治疗类风湿关节炎5年长期安全性及有效性
MOBILITY及其开放标签扩展EXTEND研究报告了沙利鲁单抗联合甲氨蝶呤治疗类风湿关节炎的5年数据,共1197例患者初始随机分组,901例进入扩展期。结果显示疗效(包括抑制影像学进展、降低疾病活动度和改善躯体功能)持续5年,安全性稳定,且沙利鲁单抗200mg组影像学进展低于150mg组和安慰剂组。
要点
- 沙利鲁单抗200mg联合甲氨蝶呤治疗5年影像学进展低于150mg组和安慰剂组。
- 临床疗效(DAS28-CRP、CDAI、HAQ-DI)持续至5年。
- 安全性稳定,中性粒细胞绝对值<1000 cells/mm3未增加感染率。
核心结论
- 沙利鲁单抗联合甲氨蝶呤治疗类风湿关节炎的临床疗效(包括抑制影像学进展、降低疾病活动度和改善躯体功能)持续5年,安全性稳定。
研究设计与样本
- MOBILITY研究(NCT01061736)将1197例中重度活动性类风湿关节炎患者随机分配至安慰剂、沙利鲁单抗150mg或200mg每2周皮下注射联合每周甲氨蝶呤治疗52周。
- 完成者进入开放标签扩展EXTEND(NCT01146652),接受沙利鲁单抗200mg每2周联合甲氨蝶呤治疗,共901例进入扩展期。
主要发现
- 5年随访安全性特征稳定,与白细胞介素-6受体阻断一致。
- 观察到中性粒细胞绝对值<1000 cells/mm3,但未与感染率增加相关。
- 初始沙利鲁单抗200mg联合甲氨蝶呤组5年影像学进展低于150mg组和安慰剂组:van der Heijde-modified Total Sharp Score自基线平均变化分别为1.46±0.27、2.35±0.28和3.68±0.27(每种沙利鲁单抗剂量与安慰剂比较p<0.001)。
- 临床疗效根据DAS28-CRP、CDAI和HAQ-DI持续至5年。
- 5年时达到CDAI≤2.8的患者数在初始随机分组间相似:安慰剂组76/398(19%),沙利鲁单抗150mg组68/400(17%),沙利鲁单抗200mg组84/399(21%)。
关键数值与推荐
- 5年时van der Heijde-modified Total Sharp Score自基线平均变化:沙利鲁单抗200mg组1.46±0.27,150mg组2.35±0.28,安慰剂组3.68±0.27(每种沙利鲁单抗剂量与安慰剂比较p<0.001)。
- 5年时达到CDAI≤2.8的患者比例:安慰剂组19%(76/398),沙利鲁单抗150mg组17%(68/400),沙利鲁单抗200mg组21%(84/399)。
临床怎么用
- 沙利鲁单抗联合甲氨蝶呤可作为甲氨蝶呤反应不足的类风湿关节炎患者的长期治疗选择,5年疗效和安全性数据支持持续使用。
- 治疗期间需监测中性粒细胞计数,但中性粒细胞绝对值<1000 cells/mm3未见感染率增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In MOBILITY (NCT01061736), sarilumab significantly reduced disease activity, improved physical function and inhibited radiographic progression at week 52 versus placebo in patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate. We report 5-year safety, efficacy and radiographic outcomes of sarilumab from NCT01061736 and the open-label extension (EXTEND; NCT01146652), in which patients received sarilumab 200 mg every 2 weeks (q2w) + methotrexate. METHODS: Patients (n=1197) with moderately to severely active RA were initially randomised to placebo, sarilumab 150 mg or sarilumab 200 mg subcutaneously q2w plus weekly methotrexate for 52 weeks. Completers were eligible to enrol in the open-label extension and receive sarilumab 200 mg q2w + methotrexate. RESULTS: Overall, 901 patients entered the open-label extension. The safety profile remained stable over 5-year follow-up and consistent with interleukin-6 receptor blockade. Absolute neutrophil count <1000 cells/mm3 was observed but not associated with increased infection rate. Initial treatment with sarilumab 200 mg + methotrexate was associated with reduced radiographic progression over 5 years versus sarilumab 150 mg + methotrexate or placebo + methotrexate (mean±SE change from baseline in van der Heijde-modified Total Sharp Score: 1.46±0.27, 2.35±0.28 and 3.68±0.27, respectively (p<0.001 for each sarilumab dose versus placebo)). Clinical efficacy was sustained through 5 years according to Disease Activity Score (28-joint count) using C reactive protein, Clinical Disease Activity Index (CDAI) and Health Assessment Questionnaire-Disability Index. The number of patients achieving CDAI ≤2.8 at 5 years was similar among initial randomisation groups (placebo, 76/398 (19%); sarilumab 150 mg, 68/400 (17%); sarilumab 200 mg, 84/399 (21%)). CONCLUSION: Clinical efficacy, including inhibition of radiographic progression, reduction in disease activity and improvement in physical function, was sustained with sarilumab + methotrexate over 5 years. Safety appeared stable over the 5-year period.
引用
- Genovese MC, van der Heijde D, Lin Y, et al. Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. RMD Open. 2019. PMID: 31452928. doi:10.1136/rmdopen-2018-000887
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。